delandistrogene moxeparvovec
SRP-9001-103
Phase 2 gene_therapy active
Quick answer
delandistrogene moxeparvovec for Muscular Dystrophy, Duchenne is a Phase 2 program (gene_therapy) at Sarepta Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Muscular Dystrophy, Duchenne
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active